MX2024010211A - Metodos y composiciones para prevenir o tratar calcifilaxis. - Google Patents
Metodos y composiciones para prevenir o tratar calcifilaxis.Info
- Publication number
- MX2024010211A MX2024010211A MX2024010211A MX2024010211A MX2024010211A MX 2024010211 A MX2024010211 A MX 2024010211A MX 2024010211 A MX2024010211 A MX 2024010211A MX 2024010211 A MX2024010211 A MX 2024010211A MX 2024010211 A MX2024010211 A MX 2024010211A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- calciphylaxis
- prevent
- subject
- Prior art date
Links
- 206010051714 Calciphylaxis Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 abstract 2
- 208000020832 chronic kidney disease Diseases 0.000 abstract 2
- VFGNPJRRTKMYKN-LJWNYQGCSA-N menaquinol-7 Chemical compound C1=CC=CC2=C(O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(O)=C21 VFGNPJRRTKMYKN-LJWNYQGCSA-N 0.000 abstract 2
- RAKQPZMEYJZGPI-LJWNYQGCSA-N menaquinone-7 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 RAKQPZMEYJZGPI-LJWNYQGCSA-N 0.000 abstract 2
- 235000009464 menaquinone-7 Nutrition 0.000 abstract 2
- 239000011700 menaquinone-7 Substances 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229940127219 anticoagulant drug Drugs 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000028208 end stage renal disease Diseases 0.000 abstract 1
- 201000000523 end stage renal failure Diseases 0.000 abstract 1
- 238000001631 haemodialysis Methods 0.000 abstract 1
- 230000000322 hemodialysis Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención proporciona métodos y composiciones para prevenir o tratar (por ejemplo, ralentizar la progresión de, detener, y/o revertir) calcifilaxis en un sujeto que lo necesita y, más particularmente, la invención está relacionada con métodos para usar menaquinona-7 (MK-7) y/o menaquinol-7 (MKH2-7) para prevenir o tratar calcifilaxis en un sujeto con uno más de los siguientes: diabetes, enfermedad renal crónica, insuficiencia renal en etapa terminal, y COPD o un sujeto sometido a hemodiálisis y/o recibiendo terapia de anticoagulante y/o terapia de estatina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862682794P | 2018-06-08 | 2018-06-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024010211A true MX2024010211A (es) | 2024-09-02 |
Family
ID=68763971
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013301A MX2020013301A (es) | 2018-06-08 | 2019-06-07 | Metodos y composiciones para prevenir o tratar calcifilaxis. |
| MX2024010211A MX2024010211A (es) | 2018-06-08 | 2020-12-07 | Metodos y composiciones para prevenir o tratar calcifilaxis. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013301A MX2020013301A (es) | 2018-06-08 | 2019-06-07 | Metodos y composiciones para prevenir o tratar calcifilaxis. |
Country Status (11)
| Country | Link |
|---|---|
| US (7) | US10736858B2 (es) |
| EP (1) | EP3801478A4 (es) |
| JP (1) | JP2021527129A (es) |
| KR (1) | KR20210018422A (es) |
| CN (1) | CN112955131A (es) |
| AU (1) | AU2019282421B2 (es) |
| CA (1) | CA3102979A1 (es) |
| IL (1) | IL279246B2 (es) |
| MX (2) | MX2020013301A (es) |
| SG (1) | SG11202012055PA (es) |
| WO (1) | WO2019237054A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112955131A (zh) | 2018-06-08 | 2021-06-11 | 埃皮松制药公司 | 用于预防或治疗钙化防御的方法和组合物 |
| EP3801477A4 (en) | 2018-06-08 | 2022-02-23 | Epizon Pharma, Inc. | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF TISSUE CALCIFICATION |
| WO2020055678A1 (en) | 2018-09-12 | 2020-03-19 | Epizon Pharma, Inc. | Menaquinol compositions and methods of treatment |
| CN113260417A (zh) * | 2019-01-04 | 2021-08-13 | 凯丹斯制药公司 | 磷酸盐结合剂与维生素k的联合疗法 |
| CN112691058A (zh) * | 2020-12-31 | 2021-04-23 | 玉溪健坤生物药业有限公司 | 一种含还原型维生素k2的牙膏及其制备方法 |
| CN114748486A (zh) * | 2022-03-25 | 2022-07-15 | 南京盛德生物科技研究院有限公司 | 一种含有维生素k2改善心血管钙化的药物组合物及其制备方法与应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050176778A1 (en) | 2001-08-03 | 2005-08-11 | Vitak Bv | Isoprenyl derivatives and their use in the title treatment and prevention of osteoporosis and cardiovascular calcification |
| WO2005030190A1 (en) | 2003-09-26 | 2005-04-07 | Natural Asa | Natural menaquinone 7 compositions |
| DE602006020658D1 (de) | 2005-06-03 | 2011-04-28 | Nattopharma Asa | Verwendung von Vitamin K, um die Verkalkung der Blutgefässe rückgängig zu machen |
| ES2790590T3 (es) * | 2006-07-14 | 2020-10-28 | Kaydence Pharma As | Productos farmacéuticos y nutricéuticos que comprenden vitamina K2 |
| GB0817528D0 (en) | 2008-09-24 | 2008-10-29 | Syntavit As | Process |
| US20130237610A1 (en) * | 2010-11-01 | 2013-09-12 | Dilip Mehta | Dynamic balancing of autonomic nervous system through vitamin mk-7 |
| GB201203705D0 (en) | 2012-03-02 | 2012-04-18 | Kappa Bioscience As | Prodrugs |
| HK1207324A1 (en) | 2012-06-18 | 2016-01-29 | 费森尤斯卡比德国有限公司 | Port cannula system for puncturing port catheters |
| WO2014191466A1 (en) | 2013-05-28 | 2014-12-04 | Nattopharma Asa | Menaquinone supplementation and vascular health |
| GB201314245D0 (en) | 2013-08-08 | 2013-09-25 | Kappa Bioscience As | Provitamins |
| WO2016131993A2 (en) * | 2015-02-20 | 2016-08-25 | Vitak B.V. | Vitamin k and capillary function |
| GEP20197040B (en) | 2015-03-20 | 2019-11-11 | Gnosis Spa | Solid forms of menaquinols |
| IT201700085412A1 (it) * | 2017-07-26 | 2019-01-26 | Pharmanutra S P A | Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare |
| US10368858B1 (en) | 2018-01-25 | 2019-08-06 | Ring Orthopedics, Inc. | Suture passer |
| EP3801477A4 (en) | 2018-06-08 | 2022-02-23 | Epizon Pharma, Inc. | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF TISSUE CALCIFICATION |
| CN112955131A (zh) | 2018-06-08 | 2021-06-11 | 埃皮松制药公司 | 用于预防或治疗钙化防御的方法和组合物 |
| WO2020055678A1 (en) | 2018-09-12 | 2020-03-19 | Epizon Pharma, Inc. | Menaquinol compositions and methods of treatment |
-
2019
- 2019-06-07 CN CN201980052691.0A patent/CN112955131A/zh active Pending
- 2019-06-07 EP EP19814419.8A patent/EP3801478A4/en active Pending
- 2019-06-07 US US16/435,230 patent/US10736858B2/en active Active
- 2019-06-07 JP JP2021518057A patent/JP2021527129A/ja active Pending
- 2019-06-07 MX MX2020013301A patent/MX2020013301A/es unknown
- 2019-06-07 CA CA3102979A patent/CA3102979A1/en active Pending
- 2019-06-07 WO PCT/US2019/036139 patent/WO2019237054A1/en active IP Right Grant
- 2019-06-07 AU AU2019282421A patent/AU2019282421B2/en active Active
- 2019-06-07 SG SG11202012055PA patent/SG11202012055PA/en unknown
- 2019-06-07 KR KR1020217000119A patent/KR20210018422A/ko active Pending
-
2020
- 2020-06-16 US US16/902,705 patent/US11065212B2/en active Active
- 2020-06-16 US US16/902,701 patent/US10925838B2/en active Active
- 2020-06-16 US US16/902,709 patent/US10987320B2/en active Active
- 2020-07-31 US US16/944,479 patent/US10940123B2/en active Active
- 2020-12-06 IL IL279246A patent/IL279246B2/en unknown
- 2020-12-07 MX MX2024010211A patent/MX2024010211A/es unknown
-
2021
- 2021-06-16 US US17/349,663 patent/US11793773B2/en active Active
-
2023
- 2023-08-07 US US18/231,035 patent/US20240041794A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021527129A (ja) | 2021-10-11 |
| KR20210018422A (ko) | 2021-02-17 |
| IL279246A (en) | 2021-01-31 |
| AU2019282421A1 (en) | 2021-01-07 |
| US11793773B2 (en) | 2023-10-24 |
| US20200306206A1 (en) | 2020-10-01 |
| CA3102979A1 (en) | 2019-12-12 |
| EP3801478A1 (en) | 2021-04-14 |
| US10940123B2 (en) | 2021-03-09 |
| US20240041794A1 (en) | 2024-02-08 |
| US10925838B2 (en) | 2021-02-23 |
| US20200306208A1 (en) | 2020-10-01 |
| WO2019237054A1 (en) | 2019-12-12 |
| US20200360301A1 (en) | 2020-11-19 |
| EP3801478A4 (en) | 2022-02-23 |
| IL279246B1 (en) | 2023-04-01 |
| SG11202012055PA (en) | 2021-01-28 |
| US10736858B2 (en) | 2020-08-11 |
| US11065212B2 (en) | 2021-07-20 |
| US20200306207A1 (en) | 2020-10-01 |
| US20210378987A1 (en) | 2021-12-09 |
| MX2020013301A (es) | 2021-05-12 |
| IL279246B2 (en) | 2023-08-01 |
| US20190374483A1 (en) | 2019-12-12 |
| US10987320B2 (en) | 2021-04-27 |
| AU2019282421B2 (en) | 2025-01-09 |
| CN112955131A (zh) | 2021-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010211A (es) | Metodos y composiciones para prevenir o tratar calcifilaxis. | |
| MX2020013302A (es) | Métodos y composiciones para prevenir o tratar calcificación de tejido. | |
| CL2019001927A1 (es) | Composiciones y métodos para el tratamiento de la anemia (divisional solicitud 201702456). | |
| PH12015502275A1 (en) | Therapuetic uses of empagliflozin | |
| MX2019005435A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| CL2018001817A1 (es) | Métodos para la inhibición de la fibrosis en un sujeto en necesidad de ellos | |
| EA201500997A1 (ru) | Терапевтические применения эмпаглифлозина | |
| BR112017020973A2 (pt) | método para tratar câncer em um paciente | |
| BR112015009948A2 (pt) | antagonistas de ativina-actriia e usos para tratamento ósseos e outros disturbios | |
| PH12018502593A1 (en) | Combinations of linagliptin and metformin | |
| EA201201284A1 (ru) | Система для обработки крови | |
| MX2023000735A (es) | Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer. | |
| MX2020009002A (es) | Fosfatasa alcalina recombinante para usarse en el tratamiento de lesion renal aguda asociada con sepsis. | |
| MX391878B (es) | Compuestos, composiciones y métodos para tratar o prevenir un síntoma asociado con la gota o la hiperuricemia. | |
| EA201891968A1 (ru) | Комбинированное лечение с использованием liv1-adc и химиотерапевтического средства | |
| CL2019003485A1 (es) | Métodos para redicur la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a. (divisional solicitud 201900909) | |
| BR112021024873A2 (pt) | Sistema de tratamento hídrico | |
| EA201990976A1 (ru) | Новый способ профилактического лечения непроизвольной потери массы | |
| MX2024006006A (es) | Metodos para tratar anemia de enfermedad renal. | |
| MX2021004174A (es) | Sistema y método para eliminar toxinas uremicas del cuerpo del paciente. | |
| PE20231306A1 (es) | Metodos de tratamiento de enfermedad renal cronica con dapagliflozina | |
| BR112015023390A2 (pt) | métodos para tratar de doença renal e outros distúrbios | |
| ZA202102023B (en) | Potentiation of helminth treatment | |
| UY39156A (es) | Métodos de tratamiento de enfermedad renal crónica con dapagliflozina | |
| EA201790868A1 (ru) | 1,2-бензотиазольные соединения для лечения почечного расстройства |